AstraZeneca plc (LON:AZN) was upgraded by research analysts at Jefferies Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The brokerage presently has a GBX 5,800 ($77.25) target price on the biopharmaceutical company’s stock, up from their previous target price of GBX 5,400 ($71.92). Jefferies Group’s price target suggests a potential upside of 13.84% from the company’s previous close.
Several other analysts have also issued reports on AZN. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Tuesday, May 17th. Credit Suisse Group AG restated an “underperform” rating and issued a GBX 4,000 ($53.28) price target on shares of AstraZeneca plc in a research report on Tuesday, May 17th. JPMorgan Chase & Co. restated a “neutral” rating on shares of AstraZeneca plc in a research report on Wednesday, May 18th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,600 ($74.59) price target on shares of AstraZeneca plc in a research report on Wednesday, May 18th. Finally, Goldman Sachs Group Inc. set a GBX 3,700 ($49.28) price target on shares of AstraZeneca plc and gave the stock a “sell” rating in a research report on Wednesday, May 18th. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. AstraZeneca plc currently has a consensus rating of “Hold” and an average price target of GBX 4,926.80 ($65.62).
AstraZeneca plc (LON:AZN) traded up 2.02% on Monday, reaching GBX 5095.00. 4,505,466 shares of the company’s stock traded hands. The firm’s 50-day moving average is GBX 5,017.86 and its 200 day moving average is GBX 4,330.50. The stock’s market capitalization is GBX 64.45 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/astrazeneca-plc-azn-raised-to-buy-at-jefferies-group.html
The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were given a GBX 68.70 ($0.92) dividend. This represents a dividend yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with MarketBeat.com’s FREE daily email newsletter.